<DOC>
	<DOCNO>NCT02348502</DOCNO>
	<brief_summary>Chronic hepatitis B ( CHB ) serious liver disease worldwide , lead cause cirrhosis hepatocellular carcinoma ( HCC ) . HBsAg loss/seroconversion consider ideal endpoint antiviral therapy HBeAg-positive -negative patient , ultimate treatment goal CHB , However HBsAg loss occur rarely interferon treatment . Although It report nature history HBsAg level≤100 IU/ml bring good long term outcomes patient chronic hepatitis B. clear whether patient achieve HBsAg level≤100 IU/ml interferon treatment could maintain sustained viral response state HBsAg level≤100 IU/ml .</brief_summary>
	<brief_title>Sustained Viral Response Patients Achieved HBsAg Level≤100 IU/ml After Completed Interferon Treatment</brief_title>
	<detailed_description>The patient chronic hepatitis B achieve HBsAg level≤100 IU/ml complete interferon treatment enrol observe 96 week . Serum HBV DNA , HBsAg , anti-HBs , HBeAg , anti-HBe measure every 3 month observation period , liver function test perform every 3 month also . The liver ultrasonic examination would take every 3-6 month . The primary endpoint HBV DNA reaction . The secondary endpoint HBsAg loss .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>patient chronic hepatitis B achieve HBsAg level≤100 IU/ml undetectable HBV DNA level interferon treatment Active consumption alcohol and/or drug Coinfection human immunodeficiency virus , hepatitis C virus , hepatitis D virus History autoimmune hepatitis Psychiatric disease Evidence neoplastic disease liver</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HBsAg loss</keyword>
	<keyword>interferon</keyword>
	<keyword>HBV reaction</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>